Century Therapeutics Inc Dossier - Source-backed chat

Century Therapeutics Inc

IPSCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.40

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.61Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $291.5M

Enterprise Value $241.9M

Shares Outstanding 200M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Century Therapeutics is a high-potential, clinical-stage biotechnology company pioneering off-the-shelf, iPSC-derived cell therapies engineered with its proprietary Allo-Evasion™ technology. By transitioning its strategic focus toward autoimmune diseases—specifically type 1 diabetes (T1D) with its lead candidate CNTY-813 and B-cell-mediated diseases with CNTY-308—Century is targeting massive, underserved markets. Backed by a robust cash runway extending into Q1 2029 following a successful $135 million private placement in early 2026, the company is well-capitalized to reach critical clinical proof-of-concept milestones, making it an attractive risk-reward opportunity for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$4.75

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0015%

Regulatory or manufacturing hurdles delay the IND submission for CNTY-813 past 2026, or early clinical trials reveal safety concerns (such as severe immune rejection or off-target toxicities). The lack of a commercial partner forces the company to fund expensive clinical trials entirely through dilutive equity raises, accelerating cash burn and depressing the stock price toward historical lows.

Base CaseCentral scenario

$4.7560%

Matches the consensus mean

Century executes on its stated timelines, submitting the IND for CNTY-813 in Q4 2026 and initiating clinical trials for both CNTY-813 and CNTY-308. The company maintains disciplined cash burn, preserving its runway into 2029. Early clinical safety and persistence data from the investigator-sponsored CARAMEL trial for CNTY-101 continue to support the viability of the iPSC platform, driving steady upward valuation toward the consensus analyst target.

Bull CaseUpside scenario

$8.0025%

CNTY-813 successfully enters the clinic in late 2026 and demonstrates durable glucose control and robust immune evasion in its initial 2027 clinical readout, establishing a potential functional cure for type 1 diabetes. Simultaneously, CNTY-308 shows superior efficacy and safety in B-cell-mediated autoimmune diseases. The validation of the Allo-Evasion™ platform attracts a major pharmaceutical partnership, triggering significant upfront payments and validating the platform's premium valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated iPSC-derived platform allowing for scalable, off-the-shelf manufacturing, bypassing the logistical and cost constraints of autologous CAR-T therapies.
Proprietary Allo-Evasion™ technology designed to prevent host immune rejection, enabling durable cell persistence and potential re-dosing without heavy immunosuppression.
Strong balance sheet with $217 million in cash and investments as of Q1 2026, providing a long runway into Q1 2029 and de-risking near-term financing needs.
Strategic pivot to high-value autoimmune indications (T1D and B-cell-mediated diseases) where cell therapy has shown transformative potential.

Key Investment Risks

Clinical development risk: All candidates are in preclinical or early clinical stages, and historical success rates for cell therapies in new indications like T1D are unproven.
Regulatory risk: Delays in IND clearances or clinical holds by the FDA could significantly impact development timelines.
No current product revenue: The company is pre-revenue and entirely dependent on clinical milestones and future collaborations to sustain its valuation.

Thesis Invalidation Triggers

Failure to submit the CNTY-813 IND by the end of 2026.
Severe adverse safety events or lack of efficacy/persistence in early clinical trials of CNTY-813 or CNTY-308.
Unexpected acceleration in cash burn rate that shortens the cash runway significantly below the Q1 2029 projection.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.